tbuckley/cabot-search huggingface dataset:
Call for Participants
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Targeting an alternate Wilms’ tumor antigen 1 peptide bypasses immunoproteasome dependency
Authors: Miranda C. Lahman, Thomas M. Schmitt, Kelly G. Paulson, Nathalie Vigneron, Denise Buenrostro, Felecia D. Wagener, Valentin Voillet, Lauren Martin, Raphael Gottardo, Jason Bielas, Julie M. McElrath, Derek L. Stirewalt, Era L. Pogosova-Agadjanyan, Cecilia C. Yeung, Robert H. Pierce, Daniel N. Egan, Merav Bar, Paul C. Hendrie, Sinéad Kinsella, Aesha Vakil, Jonah Butler, Mary Chaffee, Jonathan Linton, Megan S. McAfee, Daniel S. Hunter, Marie Bleakley, Anthony Rongvaux, Benoit J. Van den Eynde, Aude G. Chapuis, Philip D. Greenberg
Journal: Science Translational Medicine (2022)

Designing effective antileukemic immunotherapy will require understanding mechanisms underlying tumor control or resistance. Here, we report a mechanism of escape from immunologic targeting in an acute myeloid leukemia (AML) patient, who relapsed 1 year after immunotherapy with engineered T cells expressing a human leukocyte antigen A*02 (HLA-A2)–restricted T cell receptor (TCR) specific for a Wilms’ tumor antigen 1 epitope, WT1 126–134 (T TCR-C4 ). Resistance occurred despite persistence of functional therapeutic T cells and continuous expression of WT1 and HLA-A2 by the patient’s AML cells. Analysis of the recurrent AML revealed expression of the standard proteasome, but limited expression of the immunoproteasome, specifically the beta subunit 1i (β1i), which is required for presentation of WT1 126–134 . An analysis of a second patient treated with T TCR-C4 demonstrated specific loss of AML cells coexpressing β1i and WT1. To determine whether the WT1 protein continued to be processed and presented in the absence of immunoproteasome processing, we identified and tested a TCR targeting an alternative, HLA-A2–restricted WT1 37–45 epitope that was generated by immunoproteasome-deficient cells, including WT1-expressing solid tumor lines. T cells expressing this TCR (T TCR37–45 ) killed the first patients’ relapsed AML resistant to WT1 126–134 targeting, as well as other primary AML, in vitro. T TCR37–45 controlled solid tumor lines lacking immunoproteasome subunits both in vitro and in an NSG mouse model. As proteasome composition can vary in AML, defining and preferentially targeting these proteasome-independent epitopes may maximize therapeutic efficacy and potentially circumvent AML immune evasion by proteasome-related immunoediting.
Medicolegal
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
REEP6 knockout leads to defective β-adrenergic signaling in adipocytes and promotes obesity-related metabolic dysfunction.
Authors: Yeonho Son, Cheoljun Choi, Abhirup Saha, Ji-Hyun Park, Hyeonyeong Im, Yoon Keun Cho, Je Kyung Seong, Rayanne B. Burl, Elizabeth A. Rondini, James G. Granneman, Yun-Hee Lee
Journal: Metabolism (2022)
THE ABOLITION OF THE BREAD TAG.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New Vaccine Technologies
Authors: Ronald W. Ellis
Journal: JAMA (1994)

PREVENTION of disease is a tenet of all the various approaches to health care reform. One of the most effective medical interventions ever devised are vaccines, with their high level of benefit and cost-effectiveness for public health. There has never been a more exciting time for vaccine research and development, largely as a result of the implementation and refinement of a variety of new technologies. Several new vaccines have been licensed recently in different countries for routine use, including recombinant hepatitis B (HB),<i>Haemophilus influenzae</i>type b (Hib) conjugate, and hepatitis A (HA) vaccines. Several more are expected to be licensed throughout the 1990s, including acellular pertussis (for infants), varicella, and pneumococcal conjugate vaccines. Of potentially greater importance are several technological developments that, if successful, would revolutionize the way in which vaccines are produced and used. This article reviews three such developments, each of which is being researched and developed
Book Review Radiologic Maxims . By Harold Swanberg, B.Sc., M.D., F.A.C.P., Editor of The Radiolgical Review, Quincy, Illinois. With a foreword by Henry Schmitz, A.M., M.D., LL.D., F.A.C.S., Professor of Gynecology and Head of the Department, Loyola University School of Medicine, Quincy, Illinois. Radiological Review Publishing Company, 1932. Cloth. Price $1.50. 126 Pages.
Journal: New England Journal of Medicine (1933)
Miscellanea Medica
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
News from the American Heart Association
Authors: Earl Sutherland, Sutherland Kansas
Journal: Circulation Research (1974)

in Miami, Florida.One of the nation's most eminent scientists, he won the 1971 Nobel Prize in medicine or physiology for his basic research on hormones.In his discovery of cyclic AMP in 1956 at Case Western Reserve University in Cleveland, Dr. Sutherland found that this chemical in the cells translates messages from other chemicals outside the cells.Through his research work, science learned that hormones are not the sole regulatory substances in the chemistry of living organisms as had previously been believed.Born Nov.
A Call for Research to Advance Health Equity for Children Requiring Hospitalization
Authors: JoAnna K. Leyenaar
Journal: JAMA Network Open (2022)

Peter J. Gill, MD, DPhil; Thaksha Thavam, MSc; Mohammed Rashidul Anwar, MBBS, MSc; Jingqin Zhu, MSc; Patricia C. Parkin, MD; Eyal Cohen, MD, MSc; Teresa To, PhD; Sanjay Mahant, MD, MSc; Ontario Pediatric Hospital Care Study Group (OPHCSG) and the Canadian Paediatric Inpatient Research Network (PIRN); Francine Buchanan, PhD; Wenjia Chen, PhD; Ronald Cohn, MD; Mairead Green; Matt Hall, PhD; Kate Langrish, RN, BNSc, MN; Colin Macarthur, MBChB, PhD; Myla Moretti, PhD; Michelle Quinlan, BA; Ann Bayliss, MD; Ronik Kanani, MD; Sean Murray, MD; Catherine Pound, MD, MSc; Mahmoud Sakran, MD; Anupam Sehgal, MD; Sepi Taheri, MD; Gita Wahi, MD, MSc
Inhibition of IL11 Signaling Reduces Aortic Pathology in Murine Marfan Syndrome
Authors: Wei-Wen Lim, Jinrui Dong, Benjamin Ng, Anissa A. Widjaja, Chen Xie, Liping Su, Xiu-Yi Kwek, Nicole G.Z. Tee, Chee Jian Pua, Sebastian Schafer, Sivakumar Viswanathan, Stuart A. Cook
Journal: Circulation Research (2022)

Background: Marfan syndrome (MFS) is associated with TGF (transforming growth factor) β–stimulated ERK (extracellular signal-regulated kinase) activity in vascular smooth muscle cells (VSMCs), which adopt a mixed synthetic/contractile phenotype. In VSMCs, TGFβ induces IL (interleukin) 11) that stimulates ERK-dependent secretion of collagens and MMPs (matrix metalloproteinases). Here, we examined the role of IL11 in the MFS aorta. Methods: We used echocardiography, histology, immunostaining, and biochemical methods to study aortic anatomy, physiology, and molecular endophenotypes in Fbn1 C1041G/+ mice, an established murine model of MFS (mMFS). mMFS mice were crossed to an IL11-tagged EGFP (enhanced green fluorescent protein; Il11 EGFP/+ ) reporter strain or to a strain deleted for the IL11 receptor ( Il11ra1 −/− ). In therapeutic studies, mMFS were administered an X209 (neutralizing antibody against IL11RA [IL11 receptor subunit alpha]) or IgG for 20 weeks and imaged longitudinally. Results: IL11 mRNA and protein were elevated in the aortas of mMFS mice, as compared to controls. mMFS mice crossed to Il11 EGFP/+ mice had increased IL11 expression in VSMCs, notably in the aortic root and ascending aorta. As compared to the mMFS parental strain, double mutant mMFS: Il11ra1 −/ − mice had reduced aortic dilatation and exhibited lesser fibrosis, inflammation, elastin breaks, and VSMC loss, which was associated with reduced aortic COL1A1 (collagen type I alpha 1 chain), IL11, MMP2/9, and phospho-ERK expression. To explore therapeutic targeting of IL11 signaling in MFS, we administered either a neutralizing antibody against IL11RA (X209) or an IgG control. After 20 weeks of antibody administration, as compared to IgG, mMFS mice receiving X209 had reduced thoracic and abdominal aortic dilation as well as lesser fibrosis, inflammation, elastin breaks, and VSMC loss. By immunoblotting, X209 was shown to reduce aortic COL1A1, IL11, MMP2/9, and phospho-ERK expression. Conclusions: In MFS, IL11 is upregulated in aortic VSMCs to cause ERK-related thoracic aortic dilatation, inflammation, and fibrosis. Therapeutic inhibition of IL11, imminent in clinical trials, might be considered as a new approach in MFS.
Medical Applications of Porous Biomaterials: Features of Porosity and Tissue‐Specific Implications for Biocompatibility
Authors: Jamie L. Hernandez, Kim A. Woodrow
Journal: Advanced Healthcare Materials (2022)

Porosity is an important material feature commonly employed in implants and tissue scaffolds. The presence of material voids permits the infiltration of cells, mechanical compliance, and outward diffusion of pharmaceutical agents. Various studies have confirmed that porosity indeed promotes favorable tissue responses, including minimal fibrous encapsulation during the foreign body reaction (FBR). However, increased biofilm formation and calcification is also described to arise due to biomaterial porosity. Additionally, the relevance of host responses like the FBR, infection, calcification, and thrombosis are dependent on tissue location and specific tissue microenvironment. In this review, the features of porous materials and the implications of porosity in the context of medical devices is discussed. Common methods to create porous materials are also discussed, as well as the parameters that are used to tune pore features. Responses toward porous biomaterials are also reviewed, including the various stages of the FBR, hemocompatibility, biofilm formation, and calcification. Finally, these host responses are considered in tissue specific locations including the subcutis, bone, cardiovascular system, brain, eye, and female reproductive tract. The effects of porosity across the various tissues of the body is highlighted and the need to consider the tissue context when engineering biomaterials is emphasized.
Irrigation and Epuration of Sewerage.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hebrew medical ethics and the oath of Asaph
Authors: S. Muntner
Journal: JAMA (1968)

Documentation is not exact, but it may be assumed that Asaph the physician (Asaph Harofe) lived in the Middle East in the sixth century.<sup>1-6</sup>Several chapters of Asaph's<i>Book of Medicine</i>were based upon classical Hebrew texts written several hundred years before his time. These sources were edited and combined by Asaph and included in one comprehensive book to which he added several chapters, translations, and commentaries in Hebrew.<sup>7,8</sup>There is no indication of Arabic influence in this text.<sup>9</sup>The book, however, does contain reference to pagan physicians who employed modified forms of witchcraft forbidden in the biblical literature.<sup>10</sup>It has been determined without doubt that the book was written in the Near East, ie, Palestine or Babylonia.<sup>11</sup>Thus it becomes evident that the text was compiled at a period prior to the conquest of these countries by Islam, which occurred approximately 650 AD.<sup>12</sup>Asaph
Treatment of Kimura Disease With Dupilumab
Authors: Yuichi Teraki, Akane Terao
Journal: JAMA Dermatology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
T-cell–engaging Therapy for Solid Tumors
Authors: Maria de Miguel, Pablo Umana, Ana Luiza Gomes de Morais, Victor Moreno, Emiliano Calvo
Journal: Clinical Cancer Research (2020)

Abstract T-cell engagers (TCE) are a rapidly evolving novel group of treatments that have in common the concurrent engagement of a T-cell surface molecule and a tumoral cell antigen. Bispecific antibodies and genetically engineered adoptive cell therapies, as chimeric antigen receptors or T-cell receptors, have similarities and differences among their mechanisms of action, toxicity profiles, and resistance pathways. Nevertheless, the success observed in the hematologic field has not been obtained with solid tumors yet, as they are biologically more complex and have few truly tumor-specific cell surface antigens that can be targeted with high avidity T cells. Different strategies are under study to improve their short-term perspective, such as new generations of more active TCEs, multi-target or combination of different treatments approaches, or to improve the manufacturing processes. A comprehensive review of TCEs as a grouped treatment class, their current status, and research directions in their application to solid tumors therapeutics are discussed here.
Single leg vertical jump performance identifies knee function deficits at return to sport after ACL reconstruction in male athletes
Authors: Argyro Kotsifaki, Sam Van Rossom, Rod Whiteley, Vasileios Korakakis, Roald Bahr, Vasileios Sideris, Ilse Jonkers
Journal: British Journal of Sports Medicine (2022)

Vertical jump performance (height) is a more representative metric for knee function than horizontal hop performance (distance) in healthy individuals. It is not known what the biomechanical status of athletes after anterior cruciate ligament (ACL) reconstruction (ACLR) is at the time they are cleared to return to sport (RTS) or whether vertical performance metrics better evaluate knee function.Standard marker-based motion capture and electromyography (EMG) were collected from 26 male athletes cleared to RTS after ACLR and 22 control healthy subjects during single leg vertical jumps (SLJ) and single leg drop jumps (SLDJ). Performance outcomes, jump height and the Reactive Strength Index, were calculated. Sagittal plane kinematics, joint moments and joint work were obtained using inverse dynamics and lower limb muscle forces were computed using an EMG-constrained musculoskeletal model. Muscle contribution was calculated as a percentage of the impulse of all muscle forces in the model. Between-limb and between-group differences were explored using mixed models analyses.Jump performance, assessed by jump height and Reactive Strength Index, was significantly lower in the involved than the uninvolved limb and controls, with large effect sizes. For the ACLR group, jump height limb symmetry index was 83% and 77% during the SLJ and SLDJ, respectively. Work generation was significantly less in the involved knee compared to uninvolved limb and controls during the SLJ (p<0.001; d=1.19; p=0.003, d=0.91, respectively) and during the SLDJ (p<0.001; d=1.54; p=0.002, d=1.05, respectively). Hamstrings muscle contribution was greater in the involved compared to the uninvolved limb and controls, whereas soleus contribution was lower in the involved limb compared to controls.During vertical jumps, male athletes after ACLR at RTS still exhibit knee biomechanical deficits, despite symmetry in horizontal functional performance and strength tests. Vertical performance metrics like jump height and RSI can better identify interlimb asymmetries than the more commonly used hop distance and should be included in the testing battery for the RTS.
Correction to: Role of PDE10A in vascular smooth muscle cell hyperplasia and pathological vascular remodelling
Authors: Lingfeng Luo, Yujun Cai, Yishuai Zhang, Chia G Hsu, Vyacheslav A Korshunov, Xiaochun Long, Peter A Knight, Bradford C Berk, Chen Yan
Journal: Cardiovascular Research (2022)

Cardiovascular Research, cvab304, https://doi.org/10.1093/cvr/cvab304 In the originally published version of this manuscript, co-author Yujun Cai was not included in the author list. This error has now been corrected online.
Epigenetic Regulation of Nutrient Transporters in Rheumatoid Arthritis Fibroblast‐like Synoviocytes
Authors: Alyssa Torres, Brian Pedersen, Isidoro Cobo, Rizi Ai, Roxana Coras, Jessica Murillo‐Saich, Gyrid Nygaard, Elsa Sanchez‐Lopez, Anne Murphy, Wei Wang, Gary S. Firestein, Monica Guma
Journal: Arthritis & Rheumatology (2022)

Since previous studies indicate that metabolism is altered in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS), we undertook this study to determine if changes in the genome-wide chromatin and DNA states in genes associated with nutrient transporters could help to identify activated metabolic pathways in RA FLS.